Increasing prevalence of genetic disorders and advances in genomic sequencing technologies is expected to drive market expansion in the near future at a CAGR of 17.50% during the forecast period 2023 to 2032.

Market Research Future (MRFR) has published a cooked research report on the “Global Clinical Genomics Market” that contains information from 2018 to 2032. The clinical genomics market is estimated to register a CAGR of 17.50% during the forecast period of 2023 to 2032.

MRFR recognizes the following companies as the key players in the global clinical genomics market— Quest Diagnostics Incorporated (U.S.), Eurofins Scientific SE (Luxembourg), Illumina, Inc. (U.S.), PerkinElmer, Inc. (U.S.), NeoGenomics Inc. (U.S.), Foundation Medicine, Inc. (U.S.), Rosetta Genomics Ltd. (Israel), Invitae Corporation (U.S.), Myriad Genetics, Inc. (U.S.), Natera, Inc. (U.S.), Genomic Health, Inc. (U.S.), OPKO Health, Inc. (U.S.), Centogene AG (Germany), Clinical Genomics Pty Ltd. (Australia), 23andMe, Inc. (U.S.), Iverson Genetic Diagnostics, Inc. (U.S.), Veritas Genetics (U.S.), Gene by Gene, Ltd. (U.S.), GenomeDx Biosciences, Inc. (Canada), MedGenome (India), Strand Life Sciences Pvt. Ltd. (India), Beijing Genomics Institute (BGI) (China), Retrogen, Inc. (U.S.), Personalis, Inc. (U.S.), and PathGroup (U.S.) and others

Clinical Genomics Market Highlights

The global clinical genomics market is accounted to register a CAGR of 17.50% during the forecast period and is estimated to reach USD 3.41 Billion by 2032.

In the clinical genomics market, DNA from patients is analysed for diagnostic, prognostic, and therapeutic reasons utilising cutting-edge genetic testing and sequencing technology. With insights about illness risk, medication response, and other topics, it propels personalised treatment. A rising consumer need for precise healthcare solutions drives market expansion, promoting creativity and better patient results.

Segment Analysis

The global clinical genomics market has been segmented based test type, method and end user.

On the basis of test type, the market is segmented into diagnostic testing, genetic testing, newborn screening, pre-implantation testing, prenatal testing, carrier testing and other tests. The diagnostic testing segment dominated the market in 2022. The increased prevalence of both common and unusual genetic disorders has fueled the demand for diagnostic testing. Finding the genetic anomalies that underlie different diseases requires a variety of testing, enabling early detection and customised treatment plans.

Based on method, the global clinical genomics market has been segmented into molecular tests, chromosomal tests and biochemical tests. The biochemical tests segment dominated the market in 2022. Biochemical testing is necessary for the diagnosis of certain genetic disorders, metabolic diseases, and other medical conditions. With the help of these tests, specific biomarkers or abnormal quantities of metabolites, proteins, or enzymes that indicate the existence of a disease can be found.

Based on end user, the global clinical genomics market has been segmented into hospitals & clinics, government laboratories & research centres, academics and research institutes and other end users. The hospitals & clinics category generated the most income in 2022. Patients are getting more involved in managing their own health, and they are showing an increasing interest in customised care. In order to develop treatment plans that are customised to each patient's genetic profile, they search for medical institutions, such as clinics and hospitals, that can do genomic testing and analyse genetic data.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Clinical Genomics Market Research Report

Regional Analysis

The global clinical genomics market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe Clinical genomics market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Clinical genomics market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Clinical genomics market comprises of Middle East, Africa, and Latin America.

The North America clinical genomics market dominated this market in 2022 (45.80%). North America is home to many esteemed academic institutions, research facilities, and biotechnology companies that all actively contribute to the advancement of clinical genomics. These businesses develop cutting-edge genomics research, generate cutting-edge technology, and pioneer genomic applications in healthcare.

Moreover, the second-largest market share belongs to the Europe. More and more European countries are realising how crucial it is to provide genetic testing and counselling to their citizens. Genetic testing is readily available in numerous hospitals and clinics around Europe, and patients can receive genetic counselling to better understand their risks and make decisions.

Additionally, from 2023 to 2032, the Asia-Pacific clinical genomic market is anticipated to experience the quickest CAGR growth. The Asia-Pacific region is home to a large number of notable academic and research institutes that conduct cutting-edge genomics research. These organisations foster creativity, support the development of novel genomic technologies, and develop a workforce with bioinformatics and genomics knowledge.

Furthermore, as the area embraces cutting-edge genetic testing for individualised healthcare, the clinical genomics industry in Latin America is growing. Growth is influenced by increasing awareness, bettering healthcare facilities, and research partnerships. The industry is driven by tailored treatments and illness risk assessment, which encourages the integration of genetics into medical procedures for better patient care.

Key Findings of the Study

• The global clinical genomics market is expected to reach USD 3.41 Billion by 2032, at a CAGR of 17.50% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market due to the numerous prestigious academic and research institutions that carry out cutting-edge genomics research can be found throughout the Asia-Pacific area.


• Based on end user, the hospitals & clinics segment was attributed to holding the largest market in 2022.


• Quest Diagnostics Incorporated (U.S.), Eurofins Scientific SE (Luxembourg), Illumina, Inc. (U.S.), PerkinElmer, Inc. (U.S.), NeoGenomics Inc. (U.S.), Foundation Medicine, Inc. (U.S.), Rosetta Genomics Ltd. (Israel), Invitae Corporation (U.S.), Myriad Genetics, Inc. (U.S.), Natera, Inc. (U.S.), Genomic Health, Inc. (U.S.), OPKO Health, Inc. (U.S.), Centogene AG (Germany), Clinical Genomics Pty Ltd. (Australia), 23andMe, Inc. (U.S.), Iverson Genetic Diagnostics, Inc. (U.S.), Veritas Genetics (U.S.), Gene by Gene, Ltd. (U.S.), GenomeDx Biosciences, Inc. (Canada), MedGenome (India), Strand Life Sciences Pvt. Ltd. (India), Beijing Genomics Institute (BGI) (China), Retrogen, Inc. (U.S.), Personalis, Inc. (U.S.), and PathGroup (U.S.) and others